Dec 31, 2025 • Investing.com
SOMEWHAT-BULLISH
Taylor, CFO of Recursion Pharmaceuticals, sells $89k in shares
Ben R. Taylor, CFO of Recursion Pharmaceuticals (NASDAQ: RXRX), sold 21,383 shares for $89,380 on December 29, 2025, under a Rule 10b5-1 trading plan. Following this transaction, Taylor still directly owns 761,550 shares of the company's Class A Common Stock. This insider sale comes amidst other company news, including positive Phase 1b/2 results for their investigational drug REC-4881 and an upgrade from JPMorgan.
Dec 26, 2025 • Sahm
SOMEWHAT-BULLISH
Is Recursion (RXRX) Finally Proving Its AI Drug Discovery Model With REC-4881’s Early Data?
Recursion Pharmaceuticals is gaining confidence in its AI drug discovery platform, notably with positive Phase 1b/2 data for REC-4881, leading to increased institutional ownership and an upgrade from J.P. Morgan. While this strengthens the near-term outlook for the AI-first approach translating into commercially viable assets, investors remain cautious about the company's high cash burn and dependence on future funding. The positive results for REC-4881 in FAP, showing meaningful polyp burden reductions, represent a crucial test for the platform's potential.
Dec 21, 2025 • ts2.tech
SOMEWHAT-BULLISH
Recursion Pharmaceuticals RXRX Stock News and Forecasts on December 21 2025
As of December 21, 2025, investors in Recursion Pharmaceuticals (NASDAQ: RXRX) are closely watching the impact of new clinical data on the company's "AI drug discovery" promise. Positive Phase 1b/2 results for REC‑4881 in familial adenomatous polyposis (FAP) have led to a JPMorgan upgrade and an increased price target of $11, signaling potential for a significant re-rating if the platform can deliver commercial revenue. However, the company faces challenges including high cash burn and the overhang of 7.09 million shares registered for resale by Tempus AI.
Dec 15, 2025 • CNBC
NEUTRAL
Check out Recursion Pharmaceuticals's stock price (RXRX) in real time
This article provides real-time stock information for Recursion Pharmaceuticals Inc. (RXRX), including its current price, daily fluctuations, 52-week range, and key financial stats. It also highlights recent news and analyst commentary related to the company, focusing on its stock performance and clinical trial results.
Dec 01, 2025 • Sahm
NEUTRAL
Will Recursion (RXRX) Share Registration Deepen Its Tech Partnerships or Signal a Shift in Strategy?
Recursion Pharmaceuticals registered over 7 million Class A common shares for resale, issued to Tempus AI for annual license fees, indicating its strategy for asset management and partnership monetization. The company's investment case relies on AI-driven drug discovery and significant pharma partnerships, with a focus on internal programs and addressing early-stage clinical risks. Recursion Pharmaceuticals anticipates substantial revenue and earnings growth by 2028, but investors should monitor revenue concentration and evolving collaboration terms.
Dec 01, 2025 • TradingView
NEUTRAL
Recursion Pharmaceuticals Registers Resale of Tempus Shares
Recursion Pharmaceuticals (RXRX) announced the registration for resale of 7,088,742 shares of Class A common stock on November 26, 2025. These shares were issued to Tempus AI for annual license fees and the resale is registered under an automatic shelf registration, with the offering made under an exemption from the Securities Act.